Voyager Therapeutics (VYGR) Liabilities and Shareholders Equity (2014 - 2026)

Voyager Therapeutics has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $219.3 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 37.91% year-over-year to $219.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 32.73% YoY) and the FY2025 annual result came in at $252.3 million, down 35.81% from the prior year.
• Liabilities and Shareholders Equity slipped to $219.3 million in Q1 2026 per VYGR's latest filing, from $252.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $469.6 million in Q1 2024 and troughed at $159.4 million in Q4 2022.
• A 5-year average of $306.6 million and a median of $315.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity surged 120.44% in 2023, then sank 37.91% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $159.4 million in 2022, then soared by 120.44% to $351.3 million in 2023, then climbed by 11.89% to $393.0 million in 2024, then plunged by 35.81% to $252.3 million in 2025, then decreased by 13.06% to $219.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $219.3 million, $252.3 million, and $288.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.